Trials / Completed
CompletedNCT04677712
Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
MOBI: A Phase 4, Open-Label Study to Assess Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite in Adult Females
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate treatments that may mitigate bruising after QWO™ (Collagenase clostridium histolyticum \[CCH\]-aaes) treatment of cellulite in the buttocks.
Detailed description
CCH-aaes is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women. Since bruising may be bothersome, this study will investigate treatments that may mitigate bruising after treatment of cellulite in the buttocks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCH-aaes | Participants were administered CCH-aaes by subcutaneous injection to both buttocks. |
| OTHER | Compression | Participants used a compression garment on both buttocks following subcutaneous CCH-aaes injections. |
| OTHER | Cold Packs | Participants used cold packs applied to the right buttock for 5-10 minutes immediately after subcutaneous CCH-aaes injections. |
| DRUG | Arnica Gel | Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock. |
| DRUG | INhance® | Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock. |
| OTHER | PDL | Investigators applied one treatment with PDL to the right buttock between days 1-7 after injection. |
Timeline
- Start date
- 2020-12-28
- Primary completion
- 2021-06-26
- Completion
- 2021-09-02
- First posted
- 2020-12-21
- Last updated
- 2023-08-21
- Results posted
- 2023-08-21
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04677712. Inclusion in this directory is not an endorsement.